文献类型：期刊文献

英文题名：Evaluation of Melatonin Therapy in Patients with Myocardial Ischemia-Reperfusion Injury: A Systematic Review and Meta-Analysis

作者：Lv, Tingting[1,2];Yan, Junwei[1];Lou, Yunwei[1];Zhang, Zeying[1];Ye, Mengfei[3];Zhou, Jiedong[1];Luo, Fangyi[4];Bi, Chenchen[1];Lin, Hui[2];Zhang, Jian[1];Guo, Hangyuan[2,4];Liu, Zheng[1,3]

机构：[1]Shaoxing Univ, Dept Pharmacol, Med Sch, Shaoxing, Zhejiang, Peoples R China;[2]Zhejiang Univ, Shaoxing Peoples Hosp, Dept Cardiol, Shaoxing Hosp,Sch Med, Shaoxing, Zhejiang, Peoples R China;[3]Shaoxing Seventh Peoples Hosp, Dept Psychiat, Shaoxing, Zhejiang, Peoples R China;[4]Shaoxing Univ, Dept Clin Med, Med Sch, Shaoxing, Zhejiang, Peoples R China

年份：2022

卷号：2022

外文期刊名：OXIDATIVE MEDICINE AND CELLULAR LONGEVITY

收录：SCI-EXPANDED(收录号：WOS:000780817000003)、、EI(收录号：20221211819655)、Scopus(收录号：2-s2.0-85126398816)、WOS

基金：We thank LetPub (http://www.letpub.com/) for linguistic assistance during the preparation of this manuscript. This work was funded by The National Natural Science Foundation of China (No.82174204 and No.81873120) and Zhejiang Medical Health Science and Technology Project (No. 2020KY332) and the National Training Program of Innovation and Entrepreneurship for College Students (No. 2017R10349001).

语种：英文

外文关键词：Antioxidants - Blood pressure - Function evaluation - Patient treatment

外文摘要：Objectives. We conducted a meta-analysis to quantitatively evaluate the effect of melatonin therapy on patients with myocardial ischemia-reperfusion injury (MIRI) and explore the influencing factors. Background. Although preclinical studies have shown that melatonin can alleviate MIRI, its protective effect on MIRI in patients remains controversial. Methods. We searched PubMed, the Cochrane Library, and Embase. The primary outcome was cardiac function (left ventricular ejection fraction [LVEF], left ventricular end-diastolic volume [LVEDV], and left ventricular end-systolic volume [LVESV]) and myocardial infarct parameters (total left ventricular mass and infarct size). Results. We included nine randomized controlled clinical trials with 631 subjects. Our results showed that melatonin had no significant effects on the primary outcome, but subgroup analyses indicated that when melatonin was administered by intravenous and intracoronary injection at the early stage of myocardial ischemia, LVEF was improved (P=0.03) and the infarct size was reduced (< 2.5 h, SMD: -0.86; 95% CI: -1.51 to -0.22; P=0.01), whereas when melatonin was injected at the late stage of myocardial ischemia (>= 3.5 h or 2.5 h), the results were the opposite. Furthermore, melatonin intervention reduced the level of cardiac injury markers, inflammatory cytokines, oxidation factors, and increased the level of antioxidant factors (P < 0.001). Conclusions. The results indicated that the cardioprotective function of melatonin for MIRI was influenced by the route and timing regimen of melatonin administration; the mechanism of which may be associated with the production of inflammatory cytokines, the balance of oxidation, and antioxidant factors.